Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 10,873 matching trials from the live ClinicalTrials.gov search.

Filters: Nashville, Tennessee Clear all

Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Cancer
Interventions: capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev); Drug
Lead sponsor: Herbert Hurwitz; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Harvey, Illinois • Durham, North Carolina • Nashville, Tennessee

Conditions: Essential Tremor
Interventions: JZP385, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 33 more

Conditions: Cancer
Interventions: EM-1421; Drug
Lead sponsor: Erimos Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • The Bronx, New York • Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Bortezomib, Iberdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 43
States / cities: Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more

Conditions: Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Interventions: CTIM-76; Drug
Lead sponsor: Context Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pemetrexed, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 12
States / cities: Fort Myers, Florida • Augusta, Georgia • Gainesville, Georgia + 8 more

Conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions: CC-122; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Aortic Aneurysm, Abdominal
Interventions: IMPEDE-FX RapidFill Implants, EndoVascular Aneurysm Repair; Device · Procedure
Lead sponsor: Shape Memory Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 32 more

Conditions: End Stage Renal Disease
Interventions: nutritional supplementation, exercise; Drug · Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more

Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Interventions: filgrastim, carboplatin, cisplatin, cyclophosphamide, vincristine sulfate, adjuvant therapy, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 35
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 27 more

Conditions: Hospitalized Elderly
Interventions: Ready to Drink Flavored Beverage, Ready to drink flavored beverage w/ AN 777; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 65 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 115
States / cities: Auburn, Alabama • Birmingham, Alabama • Huntsville, Alabama + 100 more

Conditions: Colorectal Neoplasms
Interventions: Nintedanib (BIBF 1120), Placebo, BSC; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • New Haven, Connecticut • Plainville, Connecticut + 11 more

Conditions: Lymphoma, Mantle Cell
Interventions: Acalabrutinib, Bendamustine, Rituximab, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 65 Years and older
Enrollment: 635 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 32
States / cities: Tucson, Arizona • Downey, California • Santa Monica, California + 27 more

Conditions: End-stage Renal Disease
Interventions: Intradialysis-yoga, Educational program; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glucocorticoids Toxicity, Glucose Intolerance
Interventions: Prednisone; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Interventions: Ubamatamab, Marlotamig, Sarilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Goodyear, Arizona • Irvine, California + 14 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Dexlansoprazole MR; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 181
States / cities: Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 178 more

Conditions: Patients Undergoing Cardiac Surgery
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Polycystic Ovary Syndrome
Interventions: Sitagliptin, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pancreatic Cancer
Interventions: Ruxolitinib, Placebo, Capecitabine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 153
States / cities: Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 150 more

Conditions: Cancer
Interventions: Vopratelimab, Ipilimumab; Drug
Lead sponsor: Jounce Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Beverly Hills, California • Los Angeles, California • Newark, Delaware + 15 more

Conditions: ACL Injury, ACL - Anterior Cruciate Ligament Rupture, ACL Sprain, ACL Tear
Interventions: CBPT-ACLR, Education; Behavioral · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 14 Years to 35 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Garfield Heights, Ohio • Nashville, Tennessee

Search by objective public record fields.

Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

The Effects of Nutrition Supplementation and Resistance Exercise During Hemodialysis

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

End-Stage Renal Disease Intra-dialysis Lifestyle Education Study

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Improving ACL Reconstruction Outcomes: CBPT